SCHEMBL13545866

SCHEMBL13545866

CN(C)CCN(Cc1ccco1)C(=O)c1noc2c1CCCC2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 7/20 0.55
▸ ALDH1A1 P00352 4/20 0.44
▸ NPC1 O15118 4/20 0.44
▸ TP53 P04637 2/20 0.44
▸ AGTR1 P30556 1/20 0.44
▸ KMT2A Q03164 4/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ LMNA P02545 2/20 0.41
▸ GFER P55789 1/20 0.41
▸ RAB9A P51151 3/20 0.40
▸ HPGD P15428 1/20 0.40
▸ MAPT P10636 3/20 0.40
▸ POLB P06746 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ ESR1 P03372 1/20 0.40
▸ NR4A1 P22736 1/20 0.40
▸ RECQL P46063 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13545864 0.89 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1NPC1TP53KMT2A
SCHEMBL13545860 0.88 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1NPC1TP53KMT2A
SCHEMBL13545881 0.85 ALDH1A1 (0.61) SMN1; SMN2ALDH1A1NPC1TP53AGTR1
SCHEMBL13545868 0.84 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1NPC1TP53KMT2A
SCHEMBL13545799 0.84 LMNA (0.54) SMN1; SMN2ALDH1A1NPC1KMT2AMEN1
SCHEMBL13545870 0.81 L3MBTL1 (0.49) SMN1; SMN2ALDH1A1TP53KMT2AMAPK1
SCHEMBL13545858 0.78 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1NPC1TP53KMT2A
SCHEMBL13545880 0.75 SMN1; SMN2 (0.60) SMN1; SMN2ALDH1A1TP53LMNAHPGD
SCHEMBL13545882 0.74 ALDH1A1 (0.59) SMN1; SMN2ALDH1A1TP53KMT2AMEN1
SCHEMBL13545811 0.73 LMNA (0.57) SMN1; SMN2ALDH1A1NPC1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100022530-A1 TETRAHYDROBENZOISOXAZOLE AND TETRAHYDROINDAZOLE DERIVATIVES AS MODULATORS OF THE MITOTIC MOTOR PROTEIN MERCK PATENT GMBH (DE) 2010-01-28 — — US disclosed
US-20100022530-A1 TETRAHYDROBENZOISOXAZOLE AND TETRAHYDROINDAZOLE DERIVATIVES AS MODULATORS OF THE MITOTIC MOTOR PROTEIN MERCK PATENT GMBH (DE) 2010-01-28 — — US disclosed
WO-2008080455-A1 TETRAHYDROBENZOISOXAZOLE - AND TETRAHYDROINDAZOLE DERIVATIVES AS MODULATORS OF THE MITOTIC MOTOR PROTEIN MERCK PATENT GMBH (DE) 2008-07-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022530-A1 TETRAHYDROBENZOISOXAZOLE AND TETRAHYDROINDAZOLE DERIVATIVES AS MODULATORS OF THE MITOTIC MOTOR PROTEIN CCNB3, TUBB3, CCNB1 SMN1; SMN2 153/4885ALDH1A1 2977/4885NPC1 4626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback